Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Diabetes Mellitus, Type 2 | 37 | 2018 | 1389 | 3.160 |
Why?
|
Prostatic Neoplasms | 28 | 2016 | 457 | 2.530 |
Why?
|
Genetic Predisposition to Disease | 37 | 2018 | 840 | 2.400 |
Why?
|
Polymorphism, Single Nucleotide | 43 | 2018 | 1080 | 2.340 |
Why?
|
Cognition Disorders | 15 | 2018 | 391 | 1.860 |
Why?
|
Exercise | 19 | 2019 | 610 | 1.480 |
Why?
|
Male | 134 | 2019 | 18012 | 1.400 |
Why?
|
Aged | 92 | 2019 | 9590 | 1.310 |
Why?
|
Genome-Wide Association Study | 26 | 2019 | 546 | 1.270 |
Why?
|
Brain | 12 | 2018 | 933 | 1.270 |
Why?
|
European Continental Ancestry Group | 21 | 2019 | 1132 | 1.230 |
Why?
|
Humans | 150 | 2019 | 29552 | 1.200 |
Why?
|
Cardiovascular Diseases | 17 | 2018 | 1058 | 1.180 |
Why?
|
African Americans | 14 | 2018 | 1375 | 1.150 |
Why?
|
Linkage Disequilibrium | 9 | 2019 | 192 | 1.120 |
Why?
|
Female | 104 | 2019 | 18379 | 1.110 |
Why?
|
Middle Aged | 72 | 2019 | 10936 | 1.030 |
Why?
|
Mobility Limitation | 12 | 2018 | 197 | 1.010 |
Why?
|
Chromosome Mapping | 8 | 2013 | 192 | 1.010 |
Why?
|
Aged, 80 and over | 51 | 2019 | 3764 | 0.980 |
Why?
|
Risk Factors | 46 | 2018 | 3600 | 0.960 |
Why?
|
Geriatric Assessment | 14 | 2018 | 363 | 0.940 |
Why?
|
Body Mass Index | 11 | 2018 | 876 | 0.840 |
Why?
|
Organ Size | 5 | 2018 | 196 | 0.780 |
Why?
|
Adiposity | 7 | 2016 | 192 | 0.780 |
Why?
|
Stroke | 8 | 2018 | 552 | 0.770 |
Why?
|
Disability Evaluation | 7 | 2018 | 215 | 0.760 |
Why?
|
Genetic Loci | 8 | 2019 | 147 | 0.710 |
Why?
|
Life Style | 12 | 2019 | 369 | 0.690 |
Why?
|
Hippocampus | 3 | 2016 | 185 | 0.680 |
Why?
|
Atherosclerosis | 14 | 2018 | 730 | 0.670 |
Why?
|
Software | 3 | 2015 | 110 | 0.670 |
Why?
|
Cognition | 8 | 2018 | 529 | 0.670 |
Why?
|
Body Composition | 5 | 2015 | 367 | 0.670 |
Why?
|
Inflammation | 8 | 2018 | 511 | 0.660 |
Why?
|
Coronary Artery Disease | 9 | 2018 | 377 | 0.630 |
Why?
|
Blood Pressure | 7 | 2018 | 813 | 0.630 |
Why?
|
Health Education | 8 | 2018 | 131 | 0.610 |
Why?
|
Magnetic Resonance Imaging | 12 | 2018 | 1225 | 0.610 |
Why?
|
Frail Elderly | 5 | 2018 | 66 | 0.610 |
Why?
|
Homocysteine | 4 | 2015 | 15 | 0.590 |
Why?
|
Pedigree | 7 | 2018 | 135 | 0.570 |
Why?
|
Epistasis, Genetic | 5 | 2018 | 44 | 0.540 |
Why?
|
Adult | 35 | 2019 | 8528 | 0.540 |
Why?
|
Peptidyl-Dipeptidase A | 2 | 2014 | 142 | 0.510 |
Why?
|
Models, Genetic | 12 | 2018 | 95 | 0.510 |
Why?
|
Vascular Diseases | 1 | 2015 | 62 | 0.500 |
Why?
|
Case-Control Studies | 18 | 2015 | 861 | 0.500 |
Why?
|
United States | 24 | 2018 | 3692 | 0.490 |
Why?
|
Cohort Studies | 17 | 2018 | 1701 | 0.470 |
Why?
|
Quantitative Trait, Heritable | 5 | 2015 | 47 | 0.460 |
Why?
|
Lipids | 3 | 2019 | 215 | 0.460 |
Why?
|
Computational Biology | 3 | 2018 | 86 | 0.450 |
Why?
|
Genetic Variation | 9 | 2018 | 251 | 0.440 |
Why?
|
Cranial Irradiation | 5 | 2013 | 84 | 0.440 |
Why?
|
Genotype | 17 | 2019 | 735 | 0.440 |
Why?
|
Insulin Resistance | 6 | 2018 | 451 | 0.440 |
Why?
|
Aging | 4 | 2016 | 891 | 0.430 |
Why?
|
Genetic Association Studies | 6 | 2016 | 148 | 0.430 |
Why?
|
Genetic Markers | 8 | 2013 | 124 | 0.420 |
Why?
|
Adipose Tissue | 5 | 2016 | 332 | 0.410 |
Why?
|
Transcobalamins | 1 | 2011 | 4 | 0.410 |
Why?
|
Quality of Life | 4 | 2018 | 833 | 0.390 |
Why?
|
Hispanic Americans | 6 | 2019 | 903 | 0.390 |
Why?
|
Obesity | 7 | 2018 | 1081 | 0.390 |
Why?
|
Models, Theoretical | 1 | 2012 | 131 | 0.380 |
Why?
|
Anxiety | 4 | 2015 | 161 | 0.370 |
Why?
|
Risk Assessment | 16 | 2018 | 1329 | 0.370 |
Why?
|
Epidemiologic Methods | 1 | 2010 | 24 | 0.360 |
Why?
|
Walking | 8 | 2017 | 185 | 0.350 |
Why?
|
Brain Ischemia | 3 | 2017 | 136 | 0.350 |
Why?
|
Chromosomes, Human, Pair 19 | 1 | 2009 | 13 | 0.340 |
Why?
|
ROC Curve | 6 | 2018 | 149 | 0.340 |
Why?
|
Models, Statistical | 4 | 2017 | 164 | 0.340 |
Why?
|
C-Reactive Protein | 5 | 2015 | 235 | 0.330 |
Why?
|
Albuminuria | 4 | 2017 | 178 | 0.330 |
Why?
|
DNA, Mitochondrial | 2 | 2018 | 30 | 0.330 |
Why?
|
Hypertension | 6 | 2018 | 918 | 0.320 |
Why?
|
Continental Population Groups | 3 | 2019 | 221 | 0.320 |
Why?
|
Polymorphism, Genetic | 5 | 2014 | 200 | 0.310 |
Why?
|
Phenotype | 10 | 2019 | 633 | 0.310 |
Why?
|
Pericardium | 4 | 2013 | 50 | 0.300 |
Why?
|
Smoking | 3 | 2019 | 441 | 0.300 |
Why?
|
Microglia | 4 | 2013 | 48 | 0.290 |
Why?
|
Quantitative Trait Loci | 6 | 2018 | 141 | 0.290 |
Why?
|
Gastrointestinal Neoplasms | 2 | 2017 | 32 | 0.290 |
Why?
|
Lower Extremity | 3 | 2017 | 97 | 0.290 |
Why?
|
Exercise Therapy | 3 | 2016 | 237 | 0.290 |
Why?
|
Absorptiometry, Photon | 2 | 2017 | 129 | 0.280 |
Why?
|
PPAR alpha | 3 | 2014 | 29 | 0.280 |
Why?
|
Logistic Models | 7 | 2013 | 729 | 0.280 |
Why?
|
Motor Activity | 4 | 2014 | 315 | 0.280 |
Why?
|
Gene Frequency | 7 | 2017 | 225 | 0.280 |
Why?
|
Tomography, X-Ray Computed | 11 | 2017 | 874 | 0.270 |
Why?
|
Alcohol Drinking | 2 | 2019 | 248 | 0.270 |
Why?
|
Algorithms | 7 | 2015 | 468 | 0.270 |
Why?
|
Cross-Sectional Studies | 12 | 2018 | 1389 | 0.260 |
Why?
|
Computer Simulation | 5 | 2016 | 212 | 0.260 |
Why?
|
Adolescent | 13 | 2019 | 3284 | 0.260 |
Why?
|
Accidents, Traffic | 2 | 2018 | 191 | 0.250 |
Why?
|
Neuropsychological Tests | 5 | 2018 | 381 | 0.240 |
Why?
|
Prostate-Specific Antigen | 6 | 2009 | 62 | 0.240 |
Why?
|
Coronary Vessels | 4 | 2018 | 151 | 0.240 |
Why?
|
Chromosomes, Human, Pair 8 | 3 | 2009 | 13 | 0.240 |
Why?
|
Chromosomes, Human, Pair 17 | 3 | 2008 | 11 | 0.240 |
Why?
|
Postoperative Complications | 3 | 2018 | 676 | 0.230 |
Why?
|
Body Weight | 5 | 2018 | 290 | 0.230 |
Why?
|
Regression Analysis | 5 | 2015 | 275 | 0.230 |
Why?
|
PPAR delta | 2 | 2013 | 3 | 0.220 |
Why?
|
Proportional Hazards Models | 8 | 2018 | 711 | 0.210 |
Why?
|
Calcinosis | 4 | 2013 | 143 | 0.210 |
Why?
|
Dementia | 2 | 2015 | 237 | 0.210 |
Why?
|
Personality Disorders | 3 | 2007 | 5 | 0.210 |
Why?
|
Family Health | 5 | 2012 | 78 | 0.210 |
Why?
|
Waist Circumference | 4 | 2016 | 90 | 0.210 |
Why?
|
Bone Density | 2 | 2017 | 183 | 0.210 |
Why?
|
Reproducibility of Results | 6 | 2018 | 727 | 0.200 |
Why?
|
Neurogenesis | 2 | 2013 | 14 | 0.200 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 2 | 2012 | 135 | 0.200 |
Why?
|
Hand Strength | 3 | 2017 | 90 | 0.200 |
Why?
|
Ethnic Groups | 4 | 2013 | 440 | 0.200 |
Why?
|
Diabetic Angiopathies | 4 | 2015 | 137 | 0.190 |
Why?
|
Single-Blind Method | 7 | 2018 | 174 | 0.190 |
Why?
|
Family | 5 | 2018 | 105 | 0.190 |
Why?
|
Pilot Projects | 6 | 2014 | 489 | 0.190 |
Why?
|
Cholesterol, HDL | 3 | 2019 | 167 | 0.190 |
Why?
|
INDEL Mutation | 2 | 2018 | 10 | 0.190 |
Why?
|
Gait | 4 | 2014 | 120 | 0.190 |
Why?
|
Radiation Injuries, Experimental | 2 | 2012 | 33 | 0.190 |
Why?
|
Transcription Factor AP-1 | 2 | 2012 | 19 | 0.190 |
Why?
|
Muscle Strength | 2 | 2018 | 145 | 0.180 |
Why?
|
Predictive Value of Tests | 5 | 2014 | 796 | 0.180 |
Why?
|
Depression | 2 | 2015 | 386 | 0.180 |
Why?
|
Activities of Daily Living | 3 | 2017 | 242 | 0.180 |
Why?
|
NF-kappa B | 2 | 2012 | 77 | 0.180 |
Why?
|
Mexican Americans | 2 | 2018 | 59 | 0.180 |
Why?
|
Interleukin-6 | 3 | 2012 | 225 | 0.180 |
Why?
|
Anxiety Disorders | 2 | 2010 | 61 | 0.180 |
Why?
|
Diabetes Complications | 3 | 2018 | 171 | 0.180 |
Why?
|
Fatty Liver | 2 | 2011 | 66 | 0.170 |
Why?
|
Alzheimer Disease | 2 | 2013 | 313 | 0.170 |
Why?
|
Blood Glucose | 3 | 2018 | 469 | 0.170 |
Why?
|
Dog Diseases | 1 | 2019 | 7 | 0.170 |
Why?
|
Stereotaxic Techniques | 1 | 2019 | 23 | 0.170 |
Why?
|
Alleles | 4 | 2013 | 252 | 0.170 |
Why?
|
Randomized Controlled Trials as Topic | 5 | 2018 | 471 | 0.170 |
Why?
|
Glomerular Filtration Rate | 3 | 2017 | 289 | 0.170 |
Why?
|
Respiratory Muscles | 1 | 2018 | 7 | 0.170 |
Why?
|
Transients and Migrants | 2 | 2019 | 280 | 0.160 |
Why?
|
Meningioma | 1 | 2019 | 51 | 0.160 |
Why?
|
Survival Analysis | 2 | 2016 | 440 | 0.160 |
Why?
|
Diagnostic and Statistical Manual of Mental Disorders | 3 | 2007 | 25 | 0.160 |
Why?
|
African Continental Ancestry Group | 6 | 2019 | 350 | 0.160 |
Why?
|
Factor Analysis, Statistical | 4 | 2012 | 71 | 0.160 |
Why?
|
Follow-Up Studies | 6 | 2017 | 2124 | 0.160 |
Why?
|
Mentors | 1 | 2018 | 29 | 0.160 |
Why?
|
Metabolome | 1 | 2018 | 31 | 0.160 |
Why?
|
Subcutaneous Fat | 2 | 2016 | 42 | 0.160 |
Why?
|
Radius | 1 | 2017 | 22 | 0.150 |
Why?
|
Mitochondrial Proteins | 1 | 2018 | 67 | 0.150 |
Why?
|
Linear Models | 6 | 2016 | 427 | 0.150 |
Why?
|
Glioma | 1 | 2019 | 133 | 0.150 |
Why?
|
Hypoglycemic Agents | 2 | 2016 | 177 | 0.150 |
Why?
|
Nerve Tissue Proteins | 2 | 2019 | 118 | 0.150 |
Why?
|
Program Evaluation | 1 | 2018 | 176 | 0.150 |
Why?
|
Fibroblast Growth Factors | 1 | 2017 | 34 | 0.150 |
Why?
|
Faculty, Medical | 1 | 2018 | 69 | 0.150 |
Why?
|
von Willebrand Factor | 1 | 2017 | 17 | 0.150 |
Why?
|
Psychiatric Status Rating Scales | 3 | 2015 | 93 | 0.150 |
Why?
|
Papillomavirus Infections | 1 | 2018 | 54 | 0.150 |
Why?
|
Glucose | 1 | 2018 | 165 | 0.150 |
Why?
|
Odds Ratio | 4 | 2014 | 448 | 0.140 |
Why?
|
Pancreaticoduodenectomy | 1 | 2017 | 21 | 0.140 |
Why?
|
Medical History Taking | 2 | 2016 | 32 | 0.140 |
Why?
|
Disabled Persons | 1 | 2017 | 89 | 0.140 |
Why?
|
Mortality | 1 | 2017 | 114 | 0.140 |
Why?
|
Plasminogen Activator Inhibitor 1 | 2 | 2009 | 46 | 0.140 |
Why?
|
Attitude to Health | 1 | 2018 | 148 | 0.140 |
Why?
|
Insulin | 3 | 2015 | 347 | 0.140 |
Why?
|
Intercellular Adhesion Molecule-1 | 2 | 2008 | 41 | 0.140 |
Why?
|
Asian Continental Ancestry Group | 5 | 2019 | 110 | 0.140 |
Why?
|
Artificial Intelligence | 2 | 2013 | 49 | 0.140 |
Why?
|
Women's Health | 1 | 2018 | 226 | 0.140 |
Why?
|
Mechanical Phenomena | 1 | 2016 | 27 | 0.140 |
Why?
|
Apolipoproteins E | 1 | 2016 | 97 | 0.140 |
Why?
|
Statistics as Topic | 1 | 2016 | 107 | 0.140 |
Why?
|
Janus Kinase 1 | 1 | 2016 | 4 | 0.140 |
Why?
|
Risk | 5 | 2017 | 293 | 0.140 |
Why?
|
Analgesics, Opioid | 1 | 2019 | 247 | 0.140 |
Why?
|
N-Acetylglucosaminyltransferases | 1 | 2016 | 6 | 0.140 |
Why?
|
Seasons | 1 | 2016 | 84 | 0.140 |
Why?
|
Area Under Curve | 3 | 2012 | 85 | 0.140 |
Why?
|
Vitamin K | 1 | 2015 | 9 | 0.140 |
Why?
|
Toll-Like Receptors | 2 | 2006 | 22 | 0.130 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2019 | 328 | 0.130 |
Why?
|
Preventive Health Services | 1 | 2016 | 31 | 0.130 |
Why?
|
Hospitalization | 1 | 2018 | 423 | 0.130 |
Why?
|
Occupational Diseases | 1 | 2016 | 83 | 0.130 |
Why?
|
Animals | 11 | 2019 | 7339 | 0.130 |
Why?
|
Prognosis | 6 | 2018 | 1372 | 0.130 |
Why?
|
Young Adult | 5 | 2019 | 2431 | 0.130 |
Why?
|
Pancreatic Neoplasms | 1 | 2017 | 133 | 0.130 |
Why?
|
DNA Methylation | 1 | 2016 | 132 | 0.130 |
Why?
|
Observer Variation | 1 | 2015 | 96 | 0.130 |
Why?
|
Wounds and Injuries | 1 | 2018 | 251 | 0.130 |
Why?
|
Multigene Family | 2 | 2013 | 47 | 0.130 |
Why?
|
Breast Neoplasms | 2 | 2019 | 680 | 0.130 |
Why?
|
Spectrin | 1 | 2014 | 5 | 0.130 |
Why?
|
Guanine Nucleotide Exchange Factors | 1 | 2014 | 12 | 0.130 |
Why?
|
Longitudinal Studies | 5 | 2017 | 727 | 0.130 |
Why?
|
Diffusion Magnetic Resonance Imaging | 1 | 2014 | 53 | 0.120 |
Why?
|
Calcium, Dietary | 1 | 2014 | 24 | 0.120 |
Why?
|
Abdominal Fat | 2 | 2012 | 46 | 0.120 |
Why?
|
Renal Insufficiency, Chronic | 2 | 2015 | 272 | 0.120 |
Why?
|
Methionine | 1 | 2014 | 7 | 0.120 |
Why?
|
Aldehyde Dehydrogenase | 1 | 2014 | 5 | 0.120 |
Why?
|
R-SNARE Proteins | 1 | 2014 | 1 | 0.120 |
Why?
|
Syntaxin 1 | 1 | 2014 | 2 | 0.120 |
Why?
|
Peripheral Vascular Diseases | 1 | 2014 | 36 | 0.120 |
Why?
|
Forced Expiratory Volume | 1 | 2014 | 113 | 0.120 |
Why?
|
Mutation | 2 | 2018 | 475 | 0.120 |
Why?
|
Tissue Plasminogen Activator | 1 | 2014 | 40 | 0.120 |
Why?
|
Genome, Human | 2 | 2017 | 129 | 0.120 |
Why?
|
Haplotypes | 3 | 2008 | 221 | 0.110 |
Why?
|
Glucuronosyltransferase | 1 | 2013 | 5 | 0.110 |
Why?
|
Brain Neoplasms | 1 | 2019 | 588 | 0.110 |
Why?
|
Bilirubin | 1 | 2013 | 22 | 0.110 |
Why?
|
Inheritance Patterns | 1 | 2013 | 10 | 0.110 |
Why?
|
Thiazoles | 1 | 2013 | 32 | 0.110 |
Why?
|
Tomography, Spiral Computed | 1 | 2013 | 18 | 0.110 |
Why?
|
North Carolina | 4 | 2019 | 1430 | 0.110 |
Why?
|
Dietary Supplements | 1 | 2014 | 172 | 0.110 |
Why?
|
Genetics, Population | 1 | 2013 | 32 | 0.110 |
Why?
|
Antihypertensive Agents | 1 | 2016 | 345 | 0.110 |
Why?
|
Uric Acid | 1 | 2013 | 24 | 0.110 |
Why?
|
Enzyme Activation | 1 | 2013 | 130 | 0.110 |
Why?
|
Blood Proteins | 1 | 2012 | 18 | 0.110 |
Why?
|
Endothelial Cells | 1 | 2014 | 180 | 0.110 |
Why?
|
Neoplasms | 1 | 2019 | 628 | 0.110 |
Why?
|
Ramipril | 1 | 2012 | 4 | 0.110 |
Why?
|
Time Factors | 4 | 2018 | 2014 | 0.110 |
Why?
|
Genetic Testing | 1 | 2012 | 90 | 0.110 |
Why?
|
Sweden | 5 | 2010 | 14 | 0.100 |
Why?
|
Heart Ventricles | 1 | 2013 | 108 | 0.100 |
Why?
|
Quality Control | 1 | 2012 | 38 | 0.100 |
Why?
|
Protein Kinases | 1 | 2012 | 28 | 0.100 |
Why?
|
Physical Fitness | 1 | 2012 | 120 | 0.100 |
Why?
|
Prostate | 1 | 2012 | 69 | 0.100 |
Why?
|
Severity of Illness Index | 2 | 2013 | 864 | 0.100 |
Why?
|
Bayes Theorem | 1 | 2012 | 69 | 0.100 |
Why?
|
Adipose Tissue, White | 1 | 2011 | 6 | 0.100 |
Why?
|
Genes | 1 | 2011 | 15 | 0.100 |
Why?
|
Sex Characteristics | 3 | 2011 | 167 | 0.100 |
Why?
|
Inflammation Mediators | 1 | 2012 | 101 | 0.100 |
Why?
|
Environment | 1 | 2011 | 51 | 0.100 |
Why?
|
Sex Factors | 4 | 2017 | 633 | 0.100 |
Why?
|
Systole | 2 | 2018 | 88 | 0.100 |
Why?
|
Tumor Necrosis Factors | 1 | 2010 | 4 | 0.100 |
Why?
|
Cerebral Cortex | 1 | 2012 | 142 | 0.100 |
Why?
|
Tumor Necrosis Factor-alpha | 2 | 2009 | 210 | 0.100 |
Why?
|
Interleukins | 1 | 2010 | 17 | 0.100 |
Why?
|
Muscle, Skeletal | 1 | 2015 | 496 | 0.090 |
Why?
|
Receptors, Tumor Necrosis Factor | 1 | 2010 | 50 | 0.090 |
Why?
|
Pennsylvania | 1 | 2010 | 77 | 0.090 |
Why?
|
Butyrylcholinesterase | 1 | 2010 | 15 | 0.090 |
Why?
|
Stroke Volume | 1 | 2013 | 282 | 0.090 |
Why?
|
Organophosphorus Compounds | 1 | 2010 | 35 | 0.090 |
Why?
|
Adiponectin | 1 | 2010 | 103 | 0.090 |
Why?
|
Tunica Media | 1 | 2010 | 29 | 0.090 |
Why?
|
Ideal Body Weight | 1 | 2009 | 7 | 0.090 |
Why?
|
Gene Expression Regulation | 3 | 2014 | 484 | 0.090 |
Why?
|
Tunica Intima | 1 | 2010 | 59 | 0.090 |
Why?
|
Carotid Artery, Common | 1 | 2010 | 37 | 0.090 |
Why?
|
Carotid Artery, Internal | 1 | 2010 | 29 | 0.090 |
Why?
|
Cerebrovascular Disorders | 1 | 2010 | 48 | 0.090 |
Why?
|
Chromosomes, Human, Pair 11 | 1 | 2009 | 24 | 0.090 |
Why?
|
Prostatic Secretory Proteins | 1 | 2009 | 1 | 0.080 |
Why?
|
Analysis of Variance | 4 | 2012 | 455 | 0.080 |
Why?
|
Chromosomes, Human, Pair 10 | 1 | 2009 | 8 | 0.080 |
Why?
|
Health | 1 | 2009 | 13 | 0.080 |
Why?
|
Physical Chromosome Mapping | 1 | 2009 | 8 | 0.080 |
Why?
|
Asthma | 2 | 2003 | 397 | 0.080 |
Why?
|
Interleukin-2 | 1 | 2009 | 33 | 0.080 |
Why?
|
Chromosomes, Human, Pair 22 | 1 | 2009 | 20 | 0.080 |
Why?
|
Multicenter Studies as Topic | 2 | 2007 | 93 | 0.080 |
Why?
|
Butyrates | 1 | 2008 | 2 | 0.080 |
Why?
|
Phenylurea Compounds | 1 | 2008 | 11 | 0.080 |
Why?
|
Patient Selection | 2 | 2007 | 257 | 0.080 |
Why?
|
Hepatocyte Nuclear Factor 1-beta | 1 | 2008 | 2 | 0.080 |
Why?
|
Tetrazoles | 1 | 2008 | 71 | 0.080 |
Why?
|
Coronary Stenosis | 1 | 2008 | 28 | 0.080 |
Why?
|
Angiotensin II Type 1 Receptor Blockers | 1 | 2008 | 68 | 0.080 |
Why?
|
Mice | 5 | 2013 | 2387 | 0.080 |
Why?
|
Prevalence | 4 | 2013 | 910 | 0.080 |
Why?
|
Imidazoles | 1 | 2008 | 104 | 0.080 |
Why?
|
Agriculture | 1 | 2010 | 174 | 0.080 |
Why?
|
Vascular Cell Adhesion Molecule-1 | 1 | 2008 | 17 | 0.080 |
Why?
|
Cholesterol, LDL | 2 | 2019 | 164 | 0.080 |
Why?
|
Triglycerides | 2 | 2019 | 218 | 0.080 |
Why?
|
Liver | 1 | 2011 | 465 | 0.080 |
Why?
|
Intra-Abdominal Fat | 1 | 2008 | 61 | 0.080 |
Why?
|
Myocardial Infarction | 1 | 2012 | 424 | 0.080 |
Why?
|
Multifactorial Inheritance | 1 | 2008 | 21 | 0.080 |
Why?
|
Community-Based Participatory Research | 2 | 2019 | 105 | 0.080 |
Why?
|
Coronary Disease | 1 | 2009 | 202 | 0.080 |
Why?
|
Pesticides | 1 | 2010 | 188 | 0.080 |
Why?
|
Models, Psychological | 1 | 2007 | 22 | 0.080 |
Why?
|
Occupational Exposure | 1 | 2010 | 223 | 0.080 |
Why?
|
Hemorheology | 1 | 2007 | 7 | 0.070 |
Why?
|
Hyperemia | 1 | 2007 | 10 | 0.070 |
Why?
|
Communication | 2 | 2018 | 124 | 0.070 |
Why?
|
Brachial Artery | 1 | 2007 | 66 | 0.070 |
Why?
|
PPAR gamma | 1 | 2007 | 45 | 0.070 |
Why?
|
Decision Support Techniques | 1 | 2008 | 104 | 0.070 |
Why?
|
Taiwan | 3 | 2011 | 9 | 0.070 |
Why?
|
Vasodilation | 1 | 2007 | 87 | 0.070 |
Why?
|
Thiazolidinediones | 1 | 2007 | 47 | 0.070 |
Why?
|
Scavenger Receptors, Class A | 1 | 2006 | 6 | 0.070 |
Why?
|
Rats | 4 | 2014 | 1609 | 0.070 |
Why?
|
Risk Reduction Behavior | 1 | 2007 | 119 | 0.070 |
Why?
|
Retrospective Studies | 3 | 2019 | 3144 | 0.070 |
Why?
|
Receptors, Interleukin-1 | 1 | 2006 | 4 | 0.070 |
Why?
|
Heart | 1 | 2007 | 165 | 0.070 |
Why?
|
Endothelium, Vascular | 1 | 2007 | 145 | 0.070 |
Why?
|
Calcium | 1 | 2008 | 302 | 0.070 |
Why?
|
Kidney Function Tests | 2 | 2017 | 102 | 0.070 |
Why?
|
Radiography | 3 | 2013 | 355 | 0.070 |
Why?
|
Nuclear Family | 2 | 2003 | 15 | 0.070 |
Why?
|
Recurrence | 2 | 2017 | 235 | 0.070 |
Why?
|
Comorbidity | 3 | 2014 | 548 | 0.070 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2019 | 643 | 0.070 |
Why?
|
Socialization | 1 | 2005 | 4 | 0.070 |
Why?
|
Age Factors | 3 | 2016 | 1120 | 0.060 |
Why?
|
Databases, Genetic | 2 | 2018 | 35 | 0.060 |
Why?
|
Rats, Inbred F344 | 3 | 2012 | 125 | 0.060 |
Why?
|
Gene Expression | 2 | 2017 | 334 | 0.060 |
Why?
|
Biopsy | 2 | 2019 | 243 | 0.060 |
Why?
|
Social Behavior | 1 | 2005 | 67 | 0.060 |
Why?
|
Drug Evaluation, Preclinical | 2 | 2019 | 59 | 0.060 |
Why?
|
Survival Rate | 2 | 2017 | 797 | 0.060 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2006 | 252 | 0.060 |
Why?
|
Ultrasonography | 3 | 2015 | 350 | 0.060 |
Why?
|
Energy Intake | 1 | 2005 | 120 | 0.060 |
Why?
|
Renal Artery | 1 | 2004 | 43 | 0.060 |
Why?
|
Chromosomes, Human, Pair 13 | 1 | 2003 | 3 | 0.060 |
Why?
|
Matched-Pair Analysis | 1 | 2003 | 11 | 0.060 |
Why?
|
Chromosomes, Human, Pair 5 | 1 | 2003 | 15 | 0.060 |
Why?
|
Incidence | 3 | 2017 | 1127 | 0.060 |
Why?
|
Adult Children | 1 | 2003 | 4 | 0.060 |
Why?
|
Chromosomes, Human, Pair 7 | 1 | 2003 | 15 | 0.060 |
Why?
|
Arteriosclerosis | 1 | 2004 | 116 | 0.060 |
Why?
|
Databases, Factual | 2 | 2018 | 333 | 0.060 |
Why?
|
Siblings | 1 | 2003 | 24 | 0.060 |
Why?
|
Treatment Outcome | 3 | 2018 | 3128 | 0.060 |
Why?
|
Kidney | 1 | 2007 | 488 | 0.060 |
Why?
|
Registries | 3 | 2010 | 280 | 0.050 |
Why?
|
Diet | 1 | 2005 | 356 | 0.050 |
Why?
|
Barbados | 1 | 2002 | 1 | 0.050 |
Why?
|
Immunoglobulin E | 1 | 2002 | 47 | 0.050 |
Why?
|
Health Behavior | 2 | 2014 | 217 | 0.050 |
Why?
|
Patient Compliance | 2 | 2016 | 213 | 0.050 |
Why?
|
Kidney Diseases | 1 | 2004 | 239 | 0.050 |
Why?
|
Europe | 2 | 2014 | 78 | 0.050 |
Why?
|
Health Status | 2 | 2017 | 373 | 0.050 |
Why?
|
Transfection | 2 | 2014 | 196 | 0.050 |
Why?
|
Interleukin-1beta | 2 | 2013 | 41 | 0.050 |
Why?
|
Electrophoretic Mobility Shift Assay | 2 | 2012 | 18 | 0.050 |
Why?
|
Phosphorylation | 2 | 2013 | 228 | 0.050 |
Why?
|
Base Sequence | 2 | 2012 | 255 | 0.050 |
Why?
|
Polymerase Chain Reaction | 2 | 2012 | 185 | 0.040 |
Why?
|
Vascular Endothelial Growth Factor B | 1 | 2019 | 5 | 0.040 |
Why?
|
Reactive Oxygen Species | 2 | 2012 | 159 | 0.040 |
Why?
|
Testicular Neoplasms | 1 | 2019 | 17 | 0.040 |
Why?
|
Cells, Cultured | 2 | 2014 | 803 | 0.040 |
Why?
|
Brazil | 1 | 2019 | 13 | 0.040 |
Why?
|
Inhalation | 1 | 2018 | 8 | 0.040 |
Why?
|
Dogs | 1 | 2019 | 117 | 0.040 |
Why?
|
Microtubule-Associated Proteins | 1 | 2019 | 33 | 0.040 |
Why?
|
Drug Tolerance | 1 | 2019 | 36 | 0.040 |
Why?
|
Oxidative Phosphorylation | 1 | 2018 | 22 | 0.040 |
Why?
|
Calcium-Binding Proteins | 1 | 2019 | 45 | 0.040 |
Why?
|
Pressure | 1 | 2018 | 54 | 0.040 |
Why?
|
Muscle Proteins | 1 | 2019 | 57 | 0.040 |
Why?
|
Injections, Spinal | 1 | 2019 | 124 | 0.040 |
Why?
|
Pain Threshold | 1 | 2019 | 95 | 0.040 |
Why?
|
Respiratory Function Tests | 1 | 2018 | 111 | 0.040 |
Why?
|
Hyperalgesia | 1 | 2019 | 88 | 0.040 |
Why?
|
Lipid Metabolism | 1 | 2019 | 101 | 0.040 |
Why?
|
Personal Satisfaction | 1 | 2018 | 26 | 0.040 |
Why?
|
Opioid-Related Disorders | 1 | 2019 | 54 | 0.040 |
Why?
|
Reference Values | 2 | 2010 | 225 | 0.040 |
Why?
|
Mexico | 1 | 2018 | 64 | 0.040 |
Why?
|
Gene Regulatory Networks | 1 | 2018 | 35 | 0.040 |
Why?
|
Metabolomics | 1 | 2018 | 46 | 0.040 |
Why?
|
Femur Neck | 1 | 2017 | 19 | 0.040 |
Why?
|
Mammaplasty | 1 | 2018 | 27 | 0.040 |
Why?
|
Diastole | 1 | 2018 | 91 | 0.040 |
Why?
|
Socioeconomic Factors | 1 | 2019 | 396 | 0.040 |
Why?
|
Transcription Factors | 1 | 2019 | 174 | 0.040 |
Why?
|
Macaca mulatta | 1 | 2019 | 323 | 0.040 |
Why?
|
Thoracic Vertebrae | 1 | 2017 | 42 | 0.040 |
Why?
|
Mastectomy | 1 | 2018 | 60 | 0.040 |
Why?
|
Preoperative Period | 1 | 2017 | 32 | 0.040 |
Why?
|
Homeostasis | 1 | 2018 | 127 | 0.040 |
Why?
|
Coronary Angiography | 1 | 2018 | 139 | 0.040 |
Why?
|
Papillomavirus Vaccines | 1 | 2018 | 36 | 0.040 |
Why?
|
Multivariate Analysis | 2 | 2009 | 638 | 0.040 |
Why?
|
Cholesterol | 1 | 2019 | 239 | 0.040 |
Why?
|
Epigenesis, Genetic | 1 | 2018 | 101 | 0.040 |
Why?
|
Membrane Proteins | 1 | 2019 | 257 | 0.040 |
Why?
|
Creatinine | 1 | 2017 | 175 | 0.040 |
Why?
|
Surgical Wound Infection | 1 | 2018 | 74 | 0.040 |
Why?
|
Physical Therapy Modalities | 1 | 2017 | 60 | 0.040 |
Why?
|
Energy Metabolism | 1 | 2018 | 139 | 0.040 |
Why?
|
Lumbar Vertebrae | 1 | 2017 | 99 | 0.040 |
Why?
|
Demography | 1 | 2017 | 105 | 0.040 |
Why?
|
Colorectal Neoplasms | 1 | 2019 | 208 | 0.040 |
Why?
|
Morbidity | 1 | 2017 | 92 | 0.040 |
Why?
|
Heterozygote | 1 | 2016 | 53 | 0.040 |
Why?
|
CpG Islands | 1 | 2016 | 44 | 0.040 |
Why?
|
Placebos | 1 | 2016 | 61 | 0.030 |
Why?
|
Probability | 1 | 2016 | 151 | 0.030 |
Why?
|
Acceleration | 1 | 2016 | 61 | 0.030 |
Why?
|
Abdominal Injuries | 1 | 2016 | 33 | 0.030 |
Why?
|
Hyperglycemia | 1 | 2016 | 82 | 0.030 |
Why?
|
Time | 1 | 2016 | 21 | 0.030 |
Why?
|
Promoter Regions, Genetic | 2 | 2009 | 214 | 0.030 |
Why?
|
Patient Acceptance of Health Care | 1 | 2018 | 156 | 0.030 |
Why?
|
Thoracic Injuries | 1 | 2016 | 50 | 0.030 |
Why?
|
Fibrinogen | 1 | 2015 | 42 | 0.030 |
Why?
|
Oxidoreductases | 1 | 2015 | 20 | 0.030 |
Why?
|
Biometry | 1 | 2015 | 12 | 0.030 |
Why?
|
Length of Stay | 1 | 2017 | 296 | 0.030 |
Why?
|
Resistance Training | 1 | 2016 | 73 | 0.030 |
Why?
|
Physical Endurance | 1 | 2015 | 31 | 0.030 |
Why?
|
Magnetic Resonance Angiography | 1 | 2015 | 64 | 0.030 |
Why?
|
Hypoglycemia | 1 | 2015 | 41 | 0.030 |
Why?
|
Quadriceps Muscle | 1 | 2015 | 31 | 0.030 |
Why?
|
Cerebrovascular Circulation | 1 | 2015 | 95 | 0.030 |
Why?
|
Diaphragm | 1 | 2015 | 46 | 0.030 |
Why?
|
Health Promotion | 2 | 2007 | 223 | 0.030 |
Why?
|
Prospective Studies | 2 | 2012 | 2046 | 0.030 |
Why?
|
Vitamins | 1 | 2015 | 61 | 0.030 |
Why?
|
Memory | 1 | 2016 | 187 | 0.030 |
Why?
|
Critical Illness | 1 | 2015 | 88 | 0.030 |
Why?
|
Spirometry | 1 | 2014 | 33 | 0.030 |
Why?
|
Intensive Care Units | 1 | 2015 | 120 | 0.030 |
Why?
|
Oxidoreductases Acting on CH-NH Group Donors | 1 | 2014 | 1 | 0.030 |
Why?
|
Vitamin B 12 | 1 | 2014 | 8 | 0.030 |
Why?
|
Carbon | 1 | 2014 | 11 | 0.030 |
Why?
|
Folic Acid | 1 | 2014 | 12 | 0.030 |
Why?
|
Child | 2 | 2010 | 2233 | 0.030 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 2 | 2004 | 152 | 0.030 |
Why?
|
Gene Silencing | 1 | 2014 | 49 | 0.030 |
Why?
|
Clinical Trials as Topic | 1 | 2015 | 299 | 0.030 |
Why?
|
Cause of Death | 1 | 2014 | 222 | 0.030 |
Why?
|
Educational Status | 1 | 2014 | 165 | 0.030 |
Why?
|
Visual Acuity | 1 | 2014 | 69 | 0.030 |
Why?
|
Up-Regulation | 1 | 2014 | 183 | 0.030 |
Why?
|
Cardiac-Gated Imaging Techniques | 1 | 2013 | 13 | 0.030 |
Why?
|
Exercise Test | 1 | 2014 | 194 | 0.030 |
Why?
|
Extracellular Signal-Regulated MAP Kinases | 1 | 2013 | 36 | 0.030 |
Why?
|
Body Weights and Measures | 1 | 2013 | 23 | 0.030 |
Why?
|
Ribosomes | 1 | 2012 | 10 | 0.030 |
Why?
|
Principal Component Analysis | 1 | 2012 | 60 | 0.030 |
Why?
|
False Negative Reactions | 1 | 2012 | 21 | 0.030 |
Why?
|
Protein Biosynthesis | 1 | 2012 | 47 | 0.030 |
Why?
|
Serum Albumin | 1 | 2012 | 53 | 0.030 |
Why?
|
Independent Living | 1 | 2013 | 85 | 0.030 |
Why?
|
Interleukin 1 Receptor Antagonist Protein | 1 | 2012 | 9 | 0.030 |
Why?
|
Cell Line, Transformed | 1 | 2012 | 14 | 0.030 |
Why?
|
Monitoring, Physiologic | 1 | 2013 | 68 | 0.030 |
Why?
|
Immunoprecipitation | 1 | 2012 | 34 | 0.030 |
Why?
|
Calibration | 1 | 2012 | 25 | 0.030 |
Why?
|
Behavior, Animal | 1 | 2014 | 264 | 0.030 |
Why?
|
Chromosomes, Human, Pair 21 | 1 | 2011 | 7 | 0.030 |
Why?
|
Intention to Treat Analysis | 1 | 2011 | 23 | 0.030 |
Why?
|
Obesity, Abdominal | 1 | 2011 | 23 | 0.020 |
Why?
|
RNA | 1 | 2012 | 89 | 0.020 |
Why?
|
Blotting, Western | 1 | 2012 | 286 | 0.020 |
Why?
|
Health Status Indicators | 1 | 2011 | 67 | 0.020 |
Why?
|
Epidemiologic Studies | 1 | 2010 | 20 | 0.020 |
Why?
|
Meta-Analysis as Topic | 1 | 2010 | 39 | 0.020 |
Why?
|
Culture | 1 | 2010 | 38 | 0.020 |
Why?
|
Social Class | 1 | 2011 | 78 | 0.020 |
Why?
|
Accidental Falls | 1 | 2012 | 211 | 0.020 |
Why?
|
Heart Rate | 1 | 2012 | 316 | 0.020 |
Why?
|
Mice, Inbred C57BL | 1 | 2013 | 713 | 0.020 |
Why?
|
Chi-Square Distribution | 1 | 2011 | 294 | 0.020 |
Why?
|
Urban Population | 1 | 2010 | 79 | 0.020 |
Why?
|
Angiotensin I | 1 | 2012 | 262 | 0.020 |
Why?
|
Psychometrics | 1 | 2010 | 129 | 0.020 |
Why?
|
Bromodeoxyuridine | 1 | 2009 | 6 | 0.020 |
Why?
|
Radiation-Protective Agents | 1 | 2009 | 5 | 0.020 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2009 | 27 | 0.020 |
Why?
|
Research Design | 1 | 2011 | 289 | 0.020 |
Why?
|
Cytokines | 1 | 2010 | 243 | 0.020 |
Why?
|
Neoplasm Invasiveness | 1 | 2010 | 189 | 0.020 |
Why?
|
Models, Biological | 1 | 2011 | 375 | 0.020 |
Why?
|
Rural Population | 1 | 2010 | 250 | 0.020 |
Why?
|
Androgens | 1 | 2009 | 25 | 0.020 |
Why?
|
Cell Survival | 1 | 2009 | 278 | 0.020 |
Why?
|
JNK Mitogen-Activated Protein Kinases | 1 | 2008 | 13 | 0.020 |
Why?
|
Luciferases | 1 | 2008 | 30 | 0.020 |
Why?
|
Immunoblotting | 1 | 2008 | 50 | 0.020 |
Why?
|
Transcriptional Activation | 1 | 2008 | 42 | 0.020 |
Why?
|
Protein Transport | 1 | 2008 | 75 | 0.020 |
Why?
|
Gamma Rays | 1 | 2008 | 24 | 0.020 |
Why?
|
Maryland | 1 | 2008 | 26 | 0.020 |
Why?
|
Cyclooxygenase 2 | 1 | 2008 | 50 | 0.020 |
Why?
|
Mice, Knockout | 1 | 2009 | 425 | 0.020 |
Why?
|
Glucose Intolerance | 1 | 2008 | 44 | 0.020 |
Why?
|
Molecular Sequence Data | 1 | 2009 | 366 | 0.020 |
Why?
|
Electrocardiography | 1 | 2013 | 571 | 0.020 |
Why?
|
Carotid Arteries | 1 | 2008 | 97 | 0.020 |
Why?
|
Sex Distribution | 1 | 2008 | 188 | 0.020 |
Why?
|
Genes, myc | 1 | 2007 | 5 | 0.020 |
Why?
|
Aorta, Abdominal | 1 | 2007 | 26 | 0.020 |
Why?
|
Personality Inventory | 1 | 2007 | 18 | 0.020 |
Why?
|
Octamer Transcription Factor-3 | 1 | 2007 | 15 | 0.020 |
Why?
|
Selection Bias | 1 | 2007 | 13 | 0.020 |
Why?
|
Transcription, Genetic | 1 | 2008 | 138 | 0.020 |
Why?
|
Diabetic Neuropathies | 1 | 2007 | 23 | 0.020 |
Why?
|
Germ-Line Mutation | 1 | 2007 | 18 | 0.020 |
Why?
|
Cell Nucleus | 1 | 2008 | 109 | 0.020 |
Why?
|
Exercise Tolerance | 1 | 2008 | 110 | 0.020 |
Why?
|
Sensitivity and Specificity | 1 | 2009 | 533 | 0.020 |
Why?
|
Tourniquets | 1 | 2007 | 11 | 0.020 |
Why?
|
Cell Proliferation | 1 | 2009 | 576 | 0.020 |
Why?
|
Stress, Mechanical | 1 | 2007 | 91 | 0.020 |
Why?
|
Hormone Replacement Therapy | 1 | 2007 | 86 | 0.020 |
Why?
|
Health Surveys | 1 | 2007 | 192 | 0.020 |
Why?
|
Radiation Dosage | 1 | 2007 | 72 | 0.020 |
Why?
|
RNA, Messenger | 1 | 2008 | 523 | 0.020 |
Why?
|
Disease-Free Survival | 1 | 2007 | 282 | 0.020 |
Why?
|
Skin | 1 | 2008 | 205 | 0.020 |
Why?
|
Estrogens | 1 | 2007 | 163 | 0.020 |
Why?
|
Toll-Like Receptor 1 | 1 | 2006 | 1 | 0.020 |
Why?
|
Toll-Like Receptor 10 | 1 | 2006 | 1 | 0.020 |
Why?
|
Toll-Like Receptor 6 | 1 | 2006 | 2 | 0.020 |
Why?
|
Random Allocation | 1 | 2007 | 214 | 0.020 |
Why?
|
DNA Mutational Analysis | 1 | 2006 | 68 | 0.020 |
Why?
|
Drug Administration Schedule | 1 | 2007 | 247 | 0.020 |
Why?
|
Neoplasm Staging | 1 | 2007 | 441 | 0.020 |
Why?
|
Baltimore | 1 | 2006 | 49 | 0.020 |
Why?
|
Age Distribution | 1 | 2006 | 199 | 0.020 |
Why?
|
Postmenopause | 1 | 2007 | 398 | 0.020 |
Why?
|
Solubility | 1 | 2004 | 39 | 0.020 |
Why?
|
Serum | 1 | 2004 | 20 | 0.020 |
Why?
|
Sequence Analysis, DNA | 1 | 2004 | 139 | 0.020 |
Why?
|
Radioimmunoassay | 1 | 2004 | 21 | 0.010 |
Why?
|
Transforming Growth Factor beta1 | 1 | 2004 | 27 | 0.010 |
Why?
|
Genetic Heterogeneity | 1 | 2003 | 13 | 0.010 |
Why?
|
DNA Primers | 1 | 2004 | 90 | 0.010 |
Why?
|
Glucose Tolerance Test | 1 | 2004 | 126 | 0.010 |
Why?
|
Residence Characteristics | 1 | 2005 | 182 | 0.010 |
Why?
|
Transforming Growth Factor beta | 1 | 2004 | 66 | 0.010 |
Why?
|
Lod Score | 1 | 2003 | 71 | 0.010 |
Why?
|
Signal Transduction | 1 | 2005 | 674 | 0.010 |
Why?
|